Inicio › Leucemia linfocítica crónica › Nueva York

Ensayos clínicos de Leucemia linfocítica crónica en Nueva York

27 estudios sobre Leucemia linfocítica crónica buscan participantes en Nueva York.

Ciudades en Nueva York

Texto oficial del estudio (inglés)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Hematology Oncology Associates of CNY at Camillus, Camillus
Memorial Sloan Kettering Commack, Commack
Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse
y 10 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04269902

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Memorial Sloan Kettering Cancer Center Mskcc, New York
New York Cancer and Blood Specialists, Shirley
Suny Upstate Medical University, Syracuse
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06846671

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

New York Oncology Hematology, P.C. ( Site 5453), Albany

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT05947851

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Cayuga Cancer Center, Ithaca
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07218341

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Mount Sinai Hospital, New York
University of Rochester, Rochester
Wilmot Cancer Institute at Webster, Webster

ReclutandoFase 3

Edades de 65 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07321652

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT06564038

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

New York Medical College, Valhalla

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Memorial Sloan Kettering Cancer Center Mskcc, New York
Optum Medical Care, Pc, Westbury

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT06943872

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

New York Oncology Hematology, P.C. ( Site 0069), Albany
Roswell Park Cancer Institute ( Site 0023), Buffalo
RPCI Oncology, PC- Northtowns ( Site 0061), Williamsville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06136559

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

NYP/Weill Cornell Medical Center, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT07061951

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Roswell Park Comprehensive Cancer Center, Buffalo
Columbia University Medical Center, New York
Weill Cornell Medical College Newyork Presbyterian Hospital, New York
y 1 más

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT05006716

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute, Buffalo

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06863402

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, New York
Research Site, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06542250

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Columbia University Medical Center, New York

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Columbia University Medical Center, New York
Weill Cornell Medical College Newyork Presbyterian Hospital, New York
Memorial Sloan Kettering Cancer Center Mskcc, New York
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06973187

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT06849713

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

University of Rochester NCORP Research Base, Rochester

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT07638007

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Icahn School of Medicine at Mount Sinai /ID# 266328, New York

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06428019

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT07218510

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Cayuga Cancer Center, Ithaca
Northwell Health, Lake Success
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
y 2 más

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Northwell Health, Lake Success
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

Roswell Park Comprehensive Cancer Center, Buffalo
Weill Cornell, New York
Montefiore Medical Center, The Bronx

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Optum Medical Care PC, Westbury

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 dic 2025 · NCT05602363

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Northwell (Northshore University/Long Island Jewish Hospitals), New Hyde Park

Reclutando

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2025 · NCT05643235

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.